Lilly Jumps After Lung Cancer Drug Patent Upheld
- Ruling says Teva infringes patent for Lilly’s No. 3 seller
- Patent covers way to administer the lung cancer treatment
This article is for subscribers only.
Eli Lilly & Co. won an appeals court ruling Thursday that upheld the validity of a patent for its lung cancer drug Alimta, helping shares rise by almost 3 percent.
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes that patent, the U.S. Court of Appeals for the Federal Circuit said in an opinion on the court’s electronic docket. Lilly rose on the news.